Enantiomerism of medicinal products – a new paradigm in environmental risk assessment

Barbara Kasprzyk-Hordern, John Bagnall, David Baker, Sian Evans

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Chiral pharmacologically active compounds (PACs) are
environmental pollutants. They enter the environment mainly through
insufficiently treated sewage, waste effluents from manufacturing
processes, runoff and sludge. They are bioactive, ubiquitous and
persistent with synergistic properties. Surprisingly, the environmental
fate and effects of PACs are assessed without taking into consideration
their enantiomeric forms (this is despite existing knowledge on
enantiomer dependant toxicity of PACs to humans, taking thalidomide
as a flagship example). Such an approach leads to an underestimation of
toxicity of PACs, incorrect environmental risk assessment, and direct
risk to the environment and human health, as PACs are likely to be
present in the environment in their non-racemic forms(in the case of
single enantiomer PACs racemisation in-vivo can also take place). This
presentation aims to discuss: The phenomenon of chirality in the context
of fate and effect of chiral pharmacologically active compounds (PACs)
in the environment Monitoring of several wastewater treatment plants
and receiving waters in the UK to study stereoselective biodegradation
of PACs Stereoselective biodegradation of PACs in river microcosms
Implications of enantiomer-dependant fate of PACs for prodecures
applied in environmental risk assessment
Original languageEnglish
Title of host publicationBook of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe)
Publication statusPublished - 2013
Event23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe) - Glasgow, UK United Kingdom
Duration: 12 May 201316 May 2013

Conference

Conference23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe)
CountryUK United Kingdom
CityGlasgow
Period12/05/1316/05/13

Fingerprint

biodegradation
toxicity
racemization
environmental fate
environmental effect
microcosm
manufacturing
sewage
sludge
effluent
runoff
environmental risk assessment
product
pollutant
monitoring
river
water
human health
effect
wastewater treatment plant

Cite this

Kasprzyk-Hordern, B., Bagnall, J., Baker, D., & Evans, S. (2013). Enantiomerism of medicinal products – a new paradigm in environmental risk assessment. In Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe)

Enantiomerism of medicinal products – a new paradigm in environmental risk assessment. / Kasprzyk-Hordern, Barbara; Bagnall, John; Baker, David; Evans, Sian.

Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe). 2013.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Kasprzyk-Hordern, B, Bagnall, J, Baker, D & Evans, S 2013, Enantiomerism of medicinal products – a new paradigm in environmental risk assessment. in Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe). 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe), Glasgow, UK United Kingdom, 12/05/13.
Kasprzyk-Hordern B, Bagnall J, Baker D, Evans S. Enantiomerism of medicinal products – a new paradigm in environmental risk assessment. In Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe). 2013
Kasprzyk-Hordern, Barbara ; Bagnall, John ; Baker, David ; Evans, Sian. / Enantiomerism of medicinal products – a new paradigm in environmental risk assessment. Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe). 2013.
@inproceedings{66cbbce76b7b4e9bbbff87727a7362fd,
title = "Enantiomerism of medicinal products – a new paradigm in environmental risk assessment",
abstract = "Chiral pharmacologically active compounds (PACs) are environmental pollutants. They enter the environment mainly through insufficiently treated sewage, waste effluents from manufacturing processes, runoff and sludge. They are bioactive, ubiquitous and persistent with synergistic properties. Surprisingly, the environmental fate and effects of PACs are assessed without taking into consideration their enantiomeric forms (this is despite existing knowledge on enantiomer dependant toxicity of PACs to humans, taking thalidomide as a flagship example). Such an approach leads to an underestimation of toxicity of PACs, incorrect environmental risk assessment, and direct risk to the environment and human health, as PACs are likely to be present in the environment in their non-racemic forms(in the case of single enantiomer PACs racemisation in-vivo can also take place). This presentation aims to discuss: The phenomenon of chirality in the context of fate and effect of chiral pharmacologically active compounds (PACs) in the environment Monitoring of several wastewater treatment plants and receiving waters in the UK to study stereoselective biodegradation of PACs Stereoselective biodegradation of PACs in river microcosms Implications of enantiomer-dependant fate of PACs for prodecures applied in environmental risk assessment",
author = "Barbara Kasprzyk-Hordern and John Bagnall and David Baker and Sian Evans",
note = "Conference abstract, SETAC Europe 23rd Annual Meeting",
year = "2013",
language = "English",
booktitle = "Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe)",

}

TY - GEN

T1 - Enantiomerism of medicinal products – a new paradigm in environmental risk assessment

AU - Kasprzyk-Hordern, Barbara

AU - Bagnall, John

AU - Baker, David

AU - Evans, Sian

N1 - Conference abstract, SETAC Europe 23rd Annual Meeting

PY - 2013

Y1 - 2013

N2 - Chiral pharmacologically active compounds (PACs) are environmental pollutants. They enter the environment mainly through insufficiently treated sewage, waste effluents from manufacturing processes, runoff and sludge. They are bioactive, ubiquitous and persistent with synergistic properties. Surprisingly, the environmental fate and effects of PACs are assessed without taking into consideration their enantiomeric forms (this is despite existing knowledge on enantiomer dependant toxicity of PACs to humans, taking thalidomide as a flagship example). Such an approach leads to an underestimation of toxicity of PACs, incorrect environmental risk assessment, and direct risk to the environment and human health, as PACs are likely to be present in the environment in their non-racemic forms(in the case of single enantiomer PACs racemisation in-vivo can also take place). This presentation aims to discuss: The phenomenon of chirality in the context of fate and effect of chiral pharmacologically active compounds (PACs) in the environment Monitoring of several wastewater treatment plants and receiving waters in the UK to study stereoselective biodegradation of PACs Stereoselective biodegradation of PACs in river microcosms Implications of enantiomer-dependant fate of PACs for prodecures applied in environmental risk assessment

AB - Chiral pharmacologically active compounds (PACs) are environmental pollutants. They enter the environment mainly through insufficiently treated sewage, waste effluents from manufacturing processes, runoff and sludge. They are bioactive, ubiquitous and persistent with synergistic properties. Surprisingly, the environmental fate and effects of PACs are assessed without taking into consideration their enantiomeric forms (this is despite existing knowledge on enantiomer dependant toxicity of PACs to humans, taking thalidomide as a flagship example). Such an approach leads to an underestimation of toxicity of PACs, incorrect environmental risk assessment, and direct risk to the environment and human health, as PACs are likely to be present in the environment in their non-racemic forms(in the case of single enantiomer PACs racemisation in-vivo can also take place). This presentation aims to discuss: The phenomenon of chirality in the context of fate and effect of chiral pharmacologically active compounds (PACs) in the environment Monitoring of several wastewater treatment plants and receiving waters in the UK to study stereoselective biodegradation of PACs Stereoselective biodegradation of PACs in river microcosms Implications of enantiomer-dependant fate of PACs for prodecures applied in environmental risk assessment

UR - http://meetings.setac.org/

UR - http://glasgow.setac.eu/

M3 - Conference contribution

BT - Book of abstracts, 23rd Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC Europe)

ER -